Creative Biolabs Released PDCD1 Therapeutic Antibody Production Service

Following the approval of Pembrolizumab by FDA, Creative Biolabs developed anti-human

PDCD1 therapeutic antibody for scientists focused in the field of cancer research.

Creative Biolabs is a biotech supplier specialized in antibody products and related services. Over
the last 10 years, it has been a leader of recombinant antibody (rAb) discovery and manufacturing,
providing high quality service to customers in academia and industry fields all over the world.

Anti-human PDCD1 therapeutic antibody is a humanized antibody used in cancer immunotherapy.

It blocks a protective mechanism on cancer cells, and allows the immune system to destroy those
cancer cells. It targets the programmed cell death 1 (PD-1) receptor, and is intended for use in
treating metastatic melanoma.

In May 2017, pembrolizumab was approved by FDA for any unresectable or metastatic solid
tumor with certain genetic qualities without regarding to the tissue type or site of the tumor, which
is a first for the FDA. Since 2017, pembrolizumab has been used via intravenous infusion to treat
inoperable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC) in certain
situations, as a second-line treatment for head and neck squamous cell carcinoma (HNSCC) after
platinum-based chemotherapy, as well as for the treatment of adult and pediatric patients with
refractory classic Hodgkin's lymphoma (cHL).

Learn more about PDCD1 antibody.

About Creative Biolabs

Creative Biolabs is specialized in providing custom biotechnology and pharmaceutical services

that cover the full scope of biotechnology needs of early antibody drug discovery and
development. As a trusted provider of cost-effective outsourcing solutions, Creative Biolabs has
been working for a large number of satisfied clients from biotechnology and pharmaceutical
companies as well as government and academic research laboratories all over the world.

Its cutting-edge hybridoma development and phage display platforms allow the production of the
most comprehensive list of recombinant antibody products and extensive service portfolio,
ranging from antibody/peptide libraries, biosimilar cell lines, chimeric antigen receptor (CAR)
products and antibody drug conjugate (ADC) to engineered antibodies, such as therapeutic
antibodies, single-domain antibodies, bispecific antibodies, intrabodies, etc.